{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:55:57Z","timestamp":1790553357401,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12635-8","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:17:06Z","timestamp":1790504226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Silencing with precision: In silico strategies for antisense oligonucleotide engineering"],"prefix":"10.1007","volume":"53","author":[{"given":"Abhigna","family":"Nagaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P.","family":"Kavana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Harendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathyamurthy","family":"Srinivasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Dharmashekara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Prasad","family":"Kollur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargav","family":"Shreevatsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Shivamallu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"issue":"1","key":"12635_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75(1):285\u2013288. https:\/\/doi.org\/10.1073\/pnas.75.1.285","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"12635_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","volume":"27","author":"ST Crooke","year":"2018","unstructured":"Crooke ST, Witztum JL, Bennett CF, Baker BF (2018) RNA-targeted therapeutics. Cell Metab 27(4):714\u2013739. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.004","journal-title":"Cell Metab"},{"key":"12635_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"25","key":"12635_CR4","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.1021\/bi700230a","volume":"46","author":"J Hu","year":"2007","unstructured":"Hu J, Corey DR (2007) Inhibiting gene expression with peptide nucleic acid [PNA]--peptide conjugates that target chromosomal DNA. Biochemistry 46(25):7581\u20137589. https:\/\/doi.org\/10.1021\/bi700230a. (Epub 2007 May 31. PMID: 17536840; PMCID: PMC2564818)","journal-title":"Biochemistry"},{"issue":"1","key":"12635_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2017.68","volume":"3","author":"NC Seeman","year":"2018","unstructured":"Seeman NC, Sleiman HF (2018) DNA nanotechnology. Nat Rev Mater 3(1):17068. https:\/\/doi.org\/10.1038\/natrevmats.2017.68","journal-title":"Nat Rev Mater"},{"key":"12635_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05075-2","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhu L, Wang X et al (2022) RNA-based therapeutics: an overview and prospectus. Cell Death Dis 13:644. https:\/\/doi.org\/10.1038\/s41419-022-05075-2","journal-title":"Cell Death Dis"},{"issue":"2","key":"12635_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1042\/BJ20041956","volume":"388","author":"B Bilanges","year":"2005","unstructured":"Bilanges B, Stokoe D (2005) Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 388(2):573\u2013583. https:\/\/doi.org\/10.1042\/BJ20041956. (PMID: 15656792; PMCID: PMC1138965)","journal-title":"Biochem J"},{"issue":"2","key":"12635_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","volume":"27","author":"ST Crooke","year":"2017","unstructured":"Crooke ST (2017) Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther 27(2):70\u201377. https:\/\/doi.org\/10.1089\/nat.2016.0656","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"12635_CR9","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism, and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584\u20131600. https:\/\/doi.org\/10.1093\/nar\/gkx1239","journal-title":"Nucleic Acids Res"},{"key":"12635_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2023.100166","volume":"20","author":"N Angrish","year":"2023","unstructured":"Angrish N, Khare G (2023) Antisense oligonucleotide-based therapeutics and its applications against bacterial infections. Med Drug Discov 20:100166. https:\/\/doi.org\/10.1016\/j.medidd.2023.100166","journal-title":"Med Drug Discov"},{"issue":"2","key":"12635_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/oli.1.2000.10.117","volume":"10","author":"F Eckstein","year":"2000","unstructured":"Eckstein F (2000) Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev 10(2):117\u2013121. https:\/\/doi.org\/10.1089\/oli.1.2000.10.117. (PMID: 10805163)","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"7","key":"12635_CR12","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1529\/biophysj.106.099283","volume":"92","author":"P Guga","year":"2007","unstructured":"Guga P, Boczkowska M, Janicka M, Maciaszek A, Kuberski S, Stec WJ (2007) Unusual thermal stability of RNA\/[RP-PS]-DNA\/RNA triplexes containing a homopurine DNA strand. Biophys J 92(7):2507\u20132515. https:\/\/doi.org\/10.1529\/biophysj.106.099283. (Epub 2007 Jan 11. PMID: 17218459; PMCID: PMC1864848)","journal-title":"Biophys J"},{"key":"12635_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.omtn.2022.05.024","volume":"28","author":"KA Doxtader Lacy","year":"2022","unstructured":"Doxtader Lacy KA, Liang XH, Zhang L, Crooke ST (2022) RNA modifications can affect RNase H1-mediated PS-ASO activity. Mol Ther Nucleic Acids 28:814\u2013828. https:\/\/doi.org\/10.1016\/j.omtn.2022.05.024. (PMID: 35664704; PMCID: PMC9136273)","journal-title":"Mol Ther Nucleic Acids"},{"key":"12635_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-89689-2_2","volume":"20","author":"RN Singh","year":"2018","unstructured":"Singh RN, Singh NN (2018) Mechanism of splicing regulation of spinal muscular atrophy genes. Adv Neurobiol 20:31\u201361. https:\/\/doi.org\/10.1007\/978-3-319-89689-2_2. (PMID:29916015; PMCID: PMC6026014)","journal-title":"Adv Neurobiol"},{"issue":"10","key":"12635_CR15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1261\/rna.653607","volume":"13","author":"A Aartsma-Rus","year":"2007","unstructured":"Aartsma-Rus A, van Ommen GJ (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13(10):1609\u20131624. https:\/\/doi.org\/10.1261\/rna.653607. (Epub 2007 Aug 7. PMID: 17684229; PMCID: PMC1986821)","journal-title":"RNA"},{"issue":"4","key":"12635_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1172\/JCI19547","volume":"112","author":"P Sazani","year":"2003","unstructured":"Sazani P, Kole R (2003) Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 112(4):481\u2013486. https:\/\/doi.org\/10.1172\/JCI19547. (PMID: 12925686; PMCID: PMC171400)","journal-title":"J Clin Invest"},{"issue":"10","key":"12635_CR17","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.bmc.2019.03.057","volume":"27","author":"J Sztuba-Solinska","year":"2019","unstructured":"Sztuba-Solinska J, Chavez-Calvillo G, Cline SE (2019) Unveiling the druggable RNA targets and small molecule therapeutics. Bioorg Med Chem 27(10):2149\u20132165. https:\/\/doi.org\/10.1016\/j.bmc.2019.03.057. (Epub 2019 Mar 30. PMID: 30981606; PMCID: PMC7126819)","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"12635_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02035-4","volume":"9","author":"X Sun","year":"2024","unstructured":"Sun X, Setrerrahmane S, Li C, Hu J, Xu H (2024) Nucleic acid drugs: recent progress and future perspectives. Signal Transduct Target Ther 9(1):316. https:\/\/doi.org\/10.1038\/s41392-024-02035-4. (PMID: 39609384; PMCID: PMC11604671)","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"12635_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1261\/rna.079498.122","volume":"29","author":"SP Pradeep","year":"2023","unstructured":"Pradeep SP, Malik S, Slack FJ, Bahal R (2023) Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. RNA 29(4):434\u2013445. https:\/\/doi.org\/10.1261\/rna.079498.122. (Epub 2023 Jan 18. PMID: 36653113; PMCID: PMC10019372)","journal-title":"RNA"},{"issue":"18","key":"12635_CR20","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377(18):1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752. (PMID: 29091570)","journal-title":"N Engl J Med"},{"issue":"7","key":"12635_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378(7):625\u2013635. https:\/\/doi.org\/10.1056\/NEJMoa1710504","journal-title":"N Engl J Med"},{"issue":"4","key":"12635_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77(4):473\u2013479. https:\/\/doi.org\/10.1007\/s40265-017-0711-7. (PMID: 28229309)","journal-title":"Drugs"},{"issue":"13","key":"12635_CR23","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116. (Epub 2015 Oct 1. PMID: 26423833)","journal-title":"Future Med Chem"},{"issue":"7","key":"12635_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/hum.2013.234","volume":"25","author":"P Disterer","year":"2014","unstructured":"Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, Khoo B (2014) Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 25(7):587\u2013598. https:\/\/doi.org\/10.1089\/hum.2013.234. (Epub 2014 Jun 19. PMID: 24826963; PMCID: PMC4098814)","journal-title":"Hum Gene Ther"},{"issue":"8","key":"12635_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","volume":"270","author":"J Kurreck","year":"2003","unstructured":"Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270(8):1628\u20131644. https:\/\/doi.org\/10.1046\/j.1432-1033.2003.03555.x. (PMID: 12694176)","journal-title":"Eur J Biochem"},{"issue":"Suppl 1","key":"12635_CR26","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/s0960-8966[02]00086-x","volume":"12","author":"A Aartsma-Rus","year":"2002","unstructured":"Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC (2002) Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12(Suppl 1):S71\u2013S77. https:\/\/doi.org\/10.1016\/s0960-8966[02]00086-x. (PMID: 12206800)","journal-title":"Neuromuscul Disord"},{"key":"12635_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.omtn.2023.04.010","volume":"32","author":"N El Boujnouni","year":"2023","unstructured":"El Boujnouni N, van der Bent ML, Willemse M, \u2019t Hoen PAC, Brock R, Wansink DG (2023) Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1. Mol Ther Nucleic Acids 32:622\u2013636. https:\/\/doi.org\/10.1016\/j.omtn.2023.04.010. (PMID: 37200862; PMCID: PMC10185704)","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"12635_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","volume":"38","author":"S Chen","year":"2024","unstructured":"Chen S, Heendeniya SN, Le BT, Rahimizadeh K, Rabiee N, Zahra QUA, Veedu RN (2024) Splice-modulating antisense oligonucleotides as therapeutics for inherited metabolic diseases. BioDrugs 38(2):177\u2013203. https:\/\/doi.org\/10.1007\/s40259-024-00644-7. (Epub 2024 Jan 22. PMID: 38252341; PMCID: PMC10912209)","journal-title":"BioDrugs"},{"issue":"10","key":"12635_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19(10):673\u2013694. https:\/\/doi.org\/10.1038\/s41573-020-0075-7. (Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031)","journal-title":"Nat Rev Drug Discov"},{"key":"12635_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100416","volume":"296","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Liang XH, Baker BF, Crooke RM (2021) Antisense technology: a review. J Biol Chem 296:100416. https:\/\/doi.org\/10.1016\/j.jbc.2021.100416. (Epub 2021 Feb 16. PMID: 33600796; PMCID: PMC8005817)","journal-title":"J Biol Chem"},{"issue":"8","key":"12635_CR31","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/nar\/gkl183","volume":"34","author":"S Davis","year":"2006","unstructured":"Davis S, Lollo B, Freier S, Esau C (2006) Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 34(8):2294\u20132304. https:\/\/doi.org\/10.1093\/nar\/gkl183. (PMID:16690972;PMCID:PMC1459537)","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"12635_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nbt.3589","volume":"34","author":"XH Liang","year":"2016","unstructured":"Liang XH, Shen W, Sun H, Migawa MT, Vickers TA, Crooke ST (2016) Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat Biotechnol 34(8):875\u2013880. https:\/\/doi.org\/10.1038\/nbt.3589. (Epub 2016 Jul 11. PMID: 27398791)","journal-title":"Nat Biotechnol"},{"issue":"11","key":"12635_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/d41573-019-00269-3","volume":"18","author":"CF Bennett","year":"2019","unstructured":"Bennett CF (2019) Antisense oligonucleotides: an emerging area in drug discovery and development. Nat Rev Drug Discovery 18(11):835\u2013836. https:\/\/doi.org\/10.1038\/d41573-019-00269-3","journal-title":"Nat Rev Drug Discovery"},{"key":"12635_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2025.1548269","volume":"13","author":"B Shreevatsa","year":"2025","unstructured":"Shreevatsa B, Nagaraj A, Dharmashekar C, Jain A, Harendra B, Siddalingegowda SV, Al-Mazroua HA, Ahmad SF, Prasad SK, Srinivasa C, Shivamallu C, Kollur SP (2025) Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management. Front Chem 13:1548269. https:\/\/doi.org\/10.3389\/fchem.2025.1548269","journal-title":"Front Chem"},{"issue":"2","key":"12635_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jacl.2014.12.008","volume":"9","author":"RD Santos","year":"2015","unstructured":"Santos RD, Raal FJ, Donovan JM, Cromwell WC (2015) Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol 9(2):201\u2013209. https:\/\/doi.org\/10.1016\/j.jacl.2014.12.008. (Epub 2014 Dec 16. PMID: 25911076)","journal-title":"J Clin Lipidol"},{"issue":"5","key":"12635_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1594","volume":"11","author":"AM Quemener","year":"2020","unstructured":"Quemener AM, Bachelot L, Forestier A, Donnou-Fournet E, Gilot D, Galibert MD (2020) The powerful world of antisense oligonucleotides: from bench to bedside. Wiley Interdiscip Rev RNA 11(5):e1594. https:\/\/doi.org\/10.1002\/wrna.1594. (Epub 2020 Mar 31. PMID: 32233021; PMCID: PMC9285911)","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"6","key":"12635_CR37","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli M, Manoharan M (2023) Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res 51(6):2529\u20132573. https:\/\/doi.org\/10.1093\/nar\/gkad067. (PMID: 36881759; PMCID: PMC10085713)","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"12635_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1089\/nat.2023.0027","volume":"33","author":"W van Roon-Mom","year":"2023","unstructured":"van Roon-Mom W, Ferguson C, Aartsma-Rus A (2023) From failure to meet the clinical endpoint to U.S. Food and Drug Administration approval: 15th antisense oligonucleotide therapy approved Qalsody [Tofersen] for treatment of SOD1 mutated amyotrophic lateral sclerosis. Nucleic Acid Ther 33(4):234\u2013237. https:\/\/doi.org\/10.1089\/nat.2023.0027. (PMID: 37581487)","journal-title":"Nucleic Acid Ther"},{"key":"12635_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6678422","author":"M Lin","year":"2021","unstructured":"Lin M, Hu X, Chang S, Chang Y, Bian W, Hu R, Wang J, Zhu Q, Qiu J (2021) Advances of antisense oligonucleotide technology in the treatment of hereditary neurodegenerative diseases. Evid Based Complement Alternat Med. https:\/\/doi.org\/10.1155\/2021\/6678422. (PMID: 34211575; PMCID: PMC8211492)","journal-title":"Evid Based Complement Alternat Med"},{"issue":"6","key":"12635_CR40","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s12265-013-9495-7","volume":"6","author":"RG Lee","year":"2013","unstructured":"Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM (2013) Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res 6(6):969\u2013980. https:\/\/doi.org\/10.1007\/s12265-013-9495-7. (Epub 2013 Jul 16. PMID: 23856914; PMCID: PMC3838598)","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"12635_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","volume":"226","author":"JK Watts","year":"2012","unstructured":"Watts JK, Corey DR (2012) Silencing disease genes in the laboratory and the clinic. J Pathol 226(2):365\u2013379. https:\/\/doi.org\/10.1002\/path.2993. (Epub 2011 Nov 9. PMID: 22069063; PMCID: PMC3916955)","journal-title":"J Pathol"},{"key":"12635_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.139186","author":"M Oprea","year":"2024","unstructured":"Oprea M, Ionita M (2024) Antisense oligonucleotides-based approaches for the treatment of multiple myeloma. Int J Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.139186. (Epub ahead of print. PMID: 39732226.17\u20133728)","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"12635_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4062\/biomolther.2023.001","volume":"31","author":"Y Kim","year":"2023","unstructured":"Kim Y (2023) Drug discovery perspectives of antisense oligonucleotides. Biomol Ther [Seoul] 31(3):241\u2013252. https:\/\/doi.org\/10.4062\/biomolther.2023.001. (Epub 2023 Mar 2. PMID: 36859811; PMCID: PMC10129852)","journal-title":"Biomol Ther [Seoul]"},{"issue":"18","key":"12635_CR44","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.1093\/nar\/gkv857","volume":"43","author":"PJ Kamola","year":"2015","unstructured":"Kamola PJ, Kitson JD, Turner G, Maratou K, Eriksson S, Panjwani A, Warnock LC, DouillardGuilloux GA, Moores K, Koppe EL, Wixted WE, Wilson PA, Gooderham NJ, Gant TW, Clark KL, Hughes SA, Edbrooke MR, Parry JD (2015) In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res 43(18):8638\u20138650. . (Epub 2015 Sep 3. PMID: 26338776; PMCID: PMC4605310) https:\/\/doi.org\/10.1093\/nar\/gkv857","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"12635_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102186","volume":"35","author":"G Hwang","year":"2024","unstructured":"Hwang G, Kwon M, Seo D, Kim DH, Lee D, Lee K, Kim E, Kang M, Ryu JH (2024) ASOptimizer: optimizing antisense oligonucleotides through deep learning for IDO1 gene regulation. Mol Ther Nucleic Acids 35(2):102186. https:\/\/doi.org\/10.1016\/j.omtn.2024.102186. (PMID: 38706632; PMCID: PMC11066473)","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"12635_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238753","volume":"16","author":"S Sciabola","year":"2021","unstructured":"Sciabola S, Xi H, Cruz D, Cao Q, Lawrence C, Zhang T, Rotstein S, Hughes JD, Caffrey DR, Stanton RV (2021) PFRED: a computational platform for siRNA and antisense oligonucleotides design. PLoS ONE 16(1):e0238753. https:\/\/doi.org\/10.1371\/journal.pone.0238753. (PMID: 33481821; PMCID: PMC7822268)","journal-title":"PLoS ONE"},{"issue":"Web Server issu","key":"12635_CR47","doi-asserted-by":"publisher","first-page":"W135","DOI":"10.1093\/nar\/gkh449","volume":"32","author":"Y Ding","year":"2004","unstructured":"Ding Y, Chan CY, Lawrence CE (2004) Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res 32(Web Server issue):W135\u2013W141. https:\/\/doi.org\/10.1093\/nar\/gkh449. (PMID: 15215366; PMCID: PMC441587)","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"12635_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cmpb.2003.09.002","volume":"75","author":"W Cui","year":"2004","unstructured":"Cui W, Ning J, Naik UP, Duncan MK (2004) OptiRNAi, an RNAi design tool. Comput Methods Programs Biomed 75(1):67\u201373. https:\/\/doi.org\/10.1016\/j.cmpb.2003.09.002. (PMID: 15158049)","journal-title":"Comput Methods Programs Biomed"},{"issue":"4","key":"12635_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl1120","volume":"35","author":"T Katoh","year":"2007","unstructured":"Katoh T, Suzuki T (2007) Specific residues at every third position of siRNA shape its efficient RNAi activity. Nucleic Acids Res 35(4):e27. https:\/\/doi.org\/10.1093\/nar\/gkl1120. (Epub 2007 Jan 26. PMID: 17259216; PMCID: PMC1851635)","journal-title":"Nucleic Acids Res"},{"key":"12635_CR50","unstructured":"http:\/\/rna.chem.t.u-tokyo.ac.jp\/cgi\/siexplorer.htm"},{"issue":"1","key":"12635_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01348-5","volume":"7","author":"I Jeddi","year":"2017","unstructured":"Jeddi I, Saiz L (2017) Three-dimensional modeling of single-stranded DNA hairpins for aptamer-based biosensors. Sci Rep 7(1):1178. https:\/\/doi.org\/10.1038\/s41598-017-01348-5","journal-title":"Sci Rep"},{"issue":"13","key":"12635_CR52","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg5955","volume":"31","author":"M Zuker","year":"2003","unstructured":"Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31(13):3406\u20133415. https:\/\/doi.org\/10.1093\/nar\/gkg5955","journal-title":"Nucleic Acids Res"},{"issue":"Web Server issu","key":"12635_CR53","doi-asserted-by":"publisher","first-page":"W70","DOI":"10.1093\/nar\/gkn188","volume":"36","author":"AR Gruber","year":"2008","unstructured":"Gruber AR, Lorenz R, Bernhart SH, Neub\u00f6ck R, Hofacker IL (2008) The Vienna RNA websuite. Nucleic Acids Res 36(Web Server issue):W70\u2013W74. https:\/\/doi.org\/10.1093\/nar\/gkn188. (Epub 2008 Apr 19. PMID: 18424795; PMCID: PMC2447809)","journal-title":"Nucleic Acids Res"},{"issue":"Web Server issu","key":"12635_CR54","doi-asserted-by":"publisher","first-page":"W277","DOI":"10.1093\/nar\/gkp367","volume":"37","author":"K Sato","year":"2009","unstructured":"Sato K, Hamada M, Asai K, Mituyama T (2009) CENTROIDFOLD: a web server for RNA secondary structure prediction. Nucleic Acids Res 37(Web Server issue):W277\u2013W280. https:\/\/doi.org\/10.1093\/nar\/gkp367. (Epub 2009 May 12. PMID: 19435882; PMCID: PMC2703931)","journal-title":"Nucleic Acids Res"},{"key":"12635_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-129","volume":"11","author":"JS Reuter","year":"2010","unstructured":"Reuter JS, Mathews DH (2010) RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics 11:129. https:\/\/doi.org\/10.1186\/1471-2105-11-129","journal-title":"BMC Bioinformatics"},{"issue":"Web Server issu","key":"12635_CR56","doi-asserted-by":"publisher","first-page":"W605","DOI":"10.1093\/nar\/gki447","volume":"33","author":"A Xayaphoummine","year":"2005","unstructured":"Xayaphoummine A, Bucher T, Isambert H (2005) Kinefold web server for RNA\/DNA folding path and structure prediction including pseudoknots and knots. Nucleic Acids Res 33(Web Server issue):W605\u2013W610. https:\/\/doi.org\/10.1093\/nar\/gki447. (PMID: 15980546; PMCID: PMC1160208)","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"12635_CR57","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/nar\/gks339","volume":"40","author":"M Popenda","year":"2012","unstructured":"Popenda M, Szachniuk M, Antczak M, Purzycka KJ, Lukasiak P, Bartol N, Blazewicz J, Adamiak RW (2012) Automated 3D structure composition for large RNAs. Nucleic Acids Res 40(14):e112. https:\/\/doi.org\/10.1093\/nar\/gks339","journal-title":"Nucleic Acids Res"},{"key":"12635_CR58","unstructured":"Schr\u00f6dinger L, DeLano W (2020) PyMOL. Retrieved from http:\/\/www.pymol.org\/pymol"},{"issue":"11","key":"12635_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, Ferrin TE (2023) UCSF ChimeraX: tools for structure building and analysis. Protein Sci: A Publ Protein Soc 32(11):e4792. https:\/\/doi.org\/10.1002\/pro.4792","journal-title":"Protein Sci: A Publ Protein Soc"},{"issue":"W1","key":"12635_CR60","doi-asserted-by":"publisher","first-page":"W26","DOI":"10.1093\/nar\/gkz394","volume":"47","author":"S Li","year":"2019","unstructured":"Li S, Olson WK, Lu X-J (2019) Web 3DNA 2.0 for the analysis, visualization, and modeling of 3D nucleic acid structures. Nucleic Acids Res 47(W1):W26\u2013W34. https:\/\/doi.org\/10.1093\/nar\/gkz394","journal-title":"Nucleic Acids Res"},{"issue":"Pt 4","key":"12635_CR61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1107\/S090744490900451X","volume":"65","author":"J Lee","year":"2009","unstructured":"Lee J, Kim SH (2009) PDB editor: a user-friendly Java-based Protein Data Bank file editor with a GUI. Acta Crystallogr D Biol Crystallogr 65(Pt 4):399\u2013402. https:\/\/doi.org\/10.1107\/S090744490900451X. (Epub 2009 Mar 19. PMID: 19307724)","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"12635_CR62","unstructured":"https:\/\/github.com\/AbhignaNagaraj\/RNA2DNA\/blob\/main\/RNA2DNA.py"},{"key":"12635_CR63","unstructured":"https:\/\/github.com\/krishnakumarbhat\/RNAtoDNA"},{"issue":"W1","key":"12635_CR64","doi-asserted-by":"publisher","first-page":"W35","DOI":"10.1093\/nar\/gkz412","volume":"47","author":"J He","year":"2019","unstructured":"He J, Wang J, Tao H, Xiao Y, Huang S-Y (2019) HNADOCK: a nucleic acid docking server for modeling RNA\/DNA\u2013RNA\/DNA 3D complex structures. Nucleic Acids Res 47(W1):W35\u2013W42. https:\/\/doi.org\/10.1093\/nar\/gkz412","journal-title":"Nucleic Acids Res"},{"key":"12635_CR65","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/s41596-020-0312-x","volume":"15","author":"Y Yan","year":"2020","unstructured":"Yan Y, Tao H, He J, Huang S-Y (2020) The HDOCK server for integrated protein\u2013protein docking. Nat Protoc 15:1829\u20131852. https:\/\/doi.org\/10.1038\/s41596-020-0312-x","journal-title":"Nat Protoc"},{"key":"12635_CR66","doi-asserted-by":"crossref","unstructured":"Honorato RV, Trellet ME, Jim\u00e9nez-Garc\u00eda B, Schaarschmidt JJ, Giulini M, Reys V, Koukos PI, Rodrigues JPGLM, Karaca E, van Zundert GCP, Roel-Touris J, van Noort CW, Jandov\u00e1 Z, Melquiond ASJ, Bonvin AMJJ (2024) The HADDOCK2.4 web server: A leap forward in integrative modeling of biomolecular complexes. Nature Protocols (in press).","DOI":"10.1038\/s41596-024-01011-0"},{"issue":"2","key":"12635_CR67","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/prot.21117","volume":"65","author":"D Kozakov","year":"2006","unstructured":"Kozakov D, Brenke R, Comeau SR, Vajda S (2006) PIPER: an FFT-based protein docking program with pairwise potentials. Proteins: Struct Funct and Bioinform 65(2):392\u2013406","journal-title":"Proteins: Struct Funct and Bioinform"},{"key":"12635_CR68","doi-asserted-by":"crossref","unstructured":"Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL, Kolossv\u00e1ry I, Moraes MA, Sacerdoti FD, Salmon JK, Shan Y, Shaw DE (2006) Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the ACM\/IEEE Conference on Supercomputing [SC06], Tampa, Florida, 11\u201317 November.","DOI":"10.1145\/1188455.1188544"},{"issue":"3","key":"12635_CR69","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/ct700301q","volume":"4","author":"B Hess","year":"2008","unstructured":"Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4(3):435\u2013447","journal-title":"J Chem Theory Comput"},{"issue":"19","key":"12635_CR70","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1093\/nar\/gkl715","volume":"34","author":"Y Shao","year":"2006","unstructured":"Shao Y, Wu Y, Chan CY, McDonough K, Ding Y (2006) Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation. Nucleic Acids Res 34(19):5660\u20135669. https:\/\/doi.org\/10.1093\/nar\/gkl715. (Epub 2006 Oct 11. PMID: 17038332; PMCID: PMC1636493)","journal-title":"Nucleic Acids Res"},{"key":"12635_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A et al (2024) Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med 4:6. https:\/\/doi.org\/10.1038\/s43856-023-00419-1","journal-title":"Commun Med"},{"issue":"3","key":"12635_CR72","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35(3):238\u2013248. https:\/\/doi.org\/10.1038\/nbt.3765","journal-title":"Nat Biotechnol"},{"issue":"2","key":"12635_CR73","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/biom10020316","volume":"10","author":"A Batista-Duharte","year":"2020","unstructured":"Batista-Duharte A, Sendra L, Herrero MJ et al (2020) Progress in the use of antisense oligonucleotides for vaccine improvement. Biomolecules 10(2):316. https:\/\/doi.org\/10.3390\/biom10020316","journal-title":"Biomolecules"},{"key":"12635_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-022-00292-4","volume":"26","author":"S Huang","year":"2022","unstructured":"Huang S, Hao X, Li Y et al (2022) Nonviral delivery systems for antisense oligonucleotide therapeutics. Biomater Res 26:49. https:\/\/doi.org\/10.1186\/s40824-022-00292-4","journal-title":"Biomater Res"},{"issue":"4","key":"12635_CR75","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013243","volume":"13","author":"SM Hammond","year":"2021","unstructured":"Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarr\u00eda L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V (2021) Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med 13(4):e13243. https:\/\/doi.org\/10.15252\/emmm.202013243. (Epub 2021 Apr 6. PMID: 33821570; PMCID: PMC8033518)","journal-title":"EMBO Mol Med"},{"issue":"12","key":"12635_CR76","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1093\/nar\/gkn342","volume":"36","author":"R Juliano","year":"2008","unstructured":"Juliano R, Alam MR, Dixit V, Kang H (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36(12):4158\u20134171. https:\/\/doi.org\/10.1093\/nar\/gkn342","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"12635_CR77","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1(5):347\u2013355 (PMID: 12489851)","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"12635_CR78","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44(14):6518\u20136548. https:\/\/doi.org\/10.1093\/nar\/gkw236. (Epub 2016 Apr 15. PMID: 27084936; PMCID: PMC5001581)","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"12635_CR79","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1007\/s00044-024-03352-7","volume":"33","author":"AA Mohammed","year":"2024","unstructured":"Mohammed AA, AlShaer D, Al Musaimi O (2024) Oligonucleotides: evolution and innovation. Med Chem Res 33(12):2204\u20132220. https:\/\/doi.org\/10.1007\/s00044-024-03352-7","journal-title":"Med Chem Res"},{"key":"12635_CR80","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie X, Yu T, Li X et al (2023) Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Sig Transduct Target Ther 8:335. https:\/\/doi.org\/10.1038\/s41392-023-01589-z","journal-title":"Sig Transduct Target Ther"},{"issue":"4","key":"12635_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102351","volume":"35","author":"J H\u00f6rberg","year":"2024","unstructured":"H\u00f6rberg J, Carlesso A, Reymer A (2024) Mechanistic insights into ASO-RNA complexation: advancing antisense oligonucleotide design strategies. Mol Ther Nucleic Acids 35(4):102351. https:\/\/doi.org\/10.1016\/j.omtn.2024.102351. (PMID: 39494149; PMCID: PMC11530825)","journal-title":"Mol Ther Nucleic Acids"},{"key":"12635_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1304342","volume":"14","author":"D Collotta","year":"2023","unstructured":"Collotta D, Bertocchi I, Chiapello E, Collino M (2023) Antisense oligonucleotides: a novel frontier in pharmacological strategy. Front Pharmacol 14:1304342. https:\/\/doi.org\/10.3389\/fphar.2023.1304342. (PMID: 38044945; PMCID: PMC10690781)","journal-title":"Front Pharmacol"},{"key":"12635_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1414658","volume":"18","author":"S McDowall","year":"2024","unstructured":"McDowall S, Aung-Htut M, Wilton S, Li D (2024) Antisense oligonucleotides and their applications in rare neurological diseases. Front Neurosci 18:1414658. https:\/\/doi.org\/10.3389\/fnins.2024.1414658. (PMID: 39376536; PMCID: PMC11456401)","journal-title":"Front Neurosci"},{"issue":"6","key":"12635_CR84","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/pros.24309","volume":"82","author":"MV Luna Velez","year":"2022","unstructured":"Luna Velez MV, Paulino da Silva Filho O, Verhaegh GW, van Hooij O, El Boujnouni N, Brock R, Schalken JA (2022) Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides. Prostate 82(6):657\u2013665. https:\/\/doi.org\/10.1002\/pros.24309. (Epub 2022 Jan 31. PMID: 35098567; PMCID: PMC9303360)","journal-title":"Prostate"},{"issue":"12","key":"12635_CR85","doi-asserted-by":"publisher","first-page":"11454","DOI":"10.1021\/acsnano.3c01186","volume":"17","author":"M Hammel","year":"2023","unstructured":"Hammel M, Fan Y, Sarode A, Byrnes AE, Zang N, Kou P, Nagapudi K, Leung D, Hoogenraad CC, Chen T, Yen CW, Hura GL (2023) Correlating the structure and gene silencing activity of oligonucleotide-loaded lipid nanoparticles using small-angle X-ray scattering. ACS Nano 17(12):11454\u201311465. https:\/\/doi.org\/10.1021\/acsnano.3c01186. (Epub 2023 Jun 6. PMID: 37279108; PMCID: PMC10311593)","journal-title":"ACS Nano"},{"issue":"9","key":"12635_CR86","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","volume":"30","author":"J Kurreck","year":"2002","unstructured":"Kurreck J, Wyszko E, Gillen C, Erdmann VA (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 30(9):1911\u20131918. https:\/\/doi.org\/10.1093\/nar\/30.9.1911. (PMID: 11972327; PMCID: PMC113840)","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"12635_CR87","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1093\/nar\/gkaa091","volume":"48","author":"F Hagelskamp","year":"2020","unstructured":"Hagelskamp F, Borland K, Ramos J, Hendrick AG, Fu D, Kellner S (2020) Broadly applicable oligonucleotide mass spectrometry for the analysis of RNA writers and erasers in vitro. Nucleic Acids Res 48(7):e41. . (PMID: 32083657; PMCID: PMC7144906) https:\/\/doi.org\/10.1093\/nar\/gkaa091","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"12635_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27020536","volume":"27","author":"AM Quemener","year":"2022","unstructured":"Quemener AM, Centomo ML, Sax SL, Panella R (2022) Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development. Molecules 27(2):536. https:\/\/doi.org\/10.3390\/molecules27020536","journal-title":"Molecules"},{"key":"12635_CR89","doi-asserted-by":"publisher","DOI":"10.1021\/bc400514t","author":"O Nakagawa","year":"2013","unstructured":"Nakagawa O, Ming X, Carver K, Juliano R (2013) Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides. Bioconjugate Chem. https:\/\/doi.org\/10.1021\/bc400514t","journal-title":"Bioconjugate Chem"},{"issue":"12","key":"12635_CR90","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1093\/nar\/gkz354","volume":"47","author":"PP Thazha","year":"2019","unstructured":"Thazha PP, Mullick AE, Lee RG et al (2019) Fatty acid conjugation enhances the potency of antisense oligonucleotides in muscle. Nucleic Acids Res 47(12):6029\u20136044. https:\/\/doi.org\/10.1093\/nar\/gkz354","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"12635_CR91","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0022-3565(25)39459-0","volume":"267","author":"PA Cossum","year":"1993","unstructured":"Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke S (1993) Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267(3):1181\u20131190 (PMID: 8166890)","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"12635_CR92","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/nar\/gkx056","volume":"45","author":"PH Hagedorn","year":"2017","unstructured":"Hagedorn PH, Hansen BR, Koch T, Lindow M (2017) Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acids Res 45(5):2262\u20132282. https:\/\/doi.org\/10.1093\/nar\/gkx056","journal-title":"Nucleic Acids Res"},{"issue":"27","key":"12635_CR93","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805\u20132816. https:\/\/doi.org\/10.1056\/NEJMoa042760","journal-title":"N Engl J Med"},{"issue":"11","key":"12635_CR94","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1021\/bc800270w","volume":"19","author":"H Kang","year":"2008","unstructured":"Kang H, Alam MR, Dixit V, Fisher M, Juliano RL (2008) Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. Bioconjug Chem 19(11):2182\u20132188. https:\/\/doi.org\/10.1021\/bc800270w. (PMID: 18826264; PMCID: PMC2645933)","journal-title":"Bioconjug Chem"},{"issue":"1","key":"12635_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15476286.2023.2293335","volume":"21","author":"A Ali","year":"2024","unstructured":"Ali A, Khatoon A, Shao C, Murtaza B, Tanveer Q, Su Z (2024) Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention. RNA Biol 21(1):1\u201318. https:\/\/doi.org\/10.1080\/15476286.2023.2293335. (Epub 2023 Dec 13. PMID: 38090817; PMCID: PMC10761088)","journal-title":"RNA Biol"},{"key":"12635_CR96","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12033-011-9456-9","volume":"51","author":"A Sindhu","year":"2012","unstructured":"Sindhu A, Arora P, Chaudhury A (2012) Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics. Mol Biotechnol 51:289\u2013302. https:\/\/doi.org\/10.1007\/s12033-011-9456-9","journal-title":"Mol Biotechnol"},{"issue":"3","key":"12635_CR97","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1172\/JCI125228","volume":"129","author":"PP Seth","year":"2019","unstructured":"Seth PP, Tanowitz M, Bennett CF (2019) Selective tissue targeting of synthetic nucleic acid drugs. J Clin Invest 129(3):915\u2013925. https:\/\/doi.org\/10.1172\/JCI125228","journal-title":"J Clin Invest"},{"key":"12635_CR98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coph.2015.07.005","volume":"24","author":"G McClorey","year":"2015","unstructured":"McClorey G, Wood MJ (2015) An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol 24:52\u201358. https:\/\/doi.org\/10.1016\/j.coph.2015.07.005. (Epub 2015 Aug 14. PMID: 26277332)","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"12635_CR99","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s0002-9394[02]01327-2","volume":"133","author":"Vitravene Study Group","year":"2002","unstructured":"Vitravene Study Group (2002) A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133(4):467\u2013474. https:\/\/doi.org\/10.1016\/s0002-9394[02]01327-2. (PMID: 11931780)","journal-title":"Am J Ophthalmol"},{"issue":"15","key":"12635_CR100","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1039\/d3cc05409h","volume":"60","author":"M Katkevics","year":"2024","unstructured":"Katkevics M, MacKay JA, Rozners E (2024) Triplex-forming peptide nucleic acids as emerging ligands to modulate structure and function of complex RNAs. Chem Commun (Camb) 60(15):1999\u20132008. https:\/\/doi.org\/10.1039\/d3cc05409h. (PMID: 38259187; PMCID: PMC10922694)","journal-title":"Chem Commun (Camb)"},{"issue":"11","key":"12635_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrp.2025.102935","volume":"6","author":"Y Lian","year":"2025","unstructured":"Lian Y, Wang A, Lin R, Ke X, Zhan X, Rongguang L, Qian T, Ghosh A, Ong AAL, Toh DK, Patil KM, Krishna MS, Dezanet C, Decout J-L, Maiti S, Wang H, Chen G (2025) A dual-affinity peptide nucleic acid for targeting miRNA-21 precursor rescues tumor repressor PTEN expression. Cell Rep Phys Sci 6(11):102935. https:\/\/doi.org\/10.1016\/j.xcrp.2025.102935","journal-title":"Cell Rep Phys Sci"},{"issue":"Database issue","key":"12635_CR102","doi-asserted-by":"publisher","first-page":"D280","DOI":"10.1093\/nar\/gkp892","volume":"38","author":"DH Turner","year":"2010","unstructured":"Turner DH, Mathews DH (2010) NNDB: the nearest neighbor database for predicting stability of nucleic acid secondary structures. Nucleic Acids Res 38(Database issue):D280\u2013D282. https:\/\/doi.org\/10.1093\/nar\/gkp892","journal-title":"Nucleic Acids Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12635-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:02:08Z","timestamp":1790550128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12635-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12635"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12635-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no competing interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the study was not conducted under any conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1639"}}